Zobrazeno 1 - 9
of 9
pro vyhledávání: '"G A, Timony"'
Autor:
Hugh Rosen, M F Boehm, Fiona Scott, J. Brooks, H. Desale, R. Powell, E. Brahmachary, E. Martinborough, H. Dedman, Robert Peach, Edward Roberts, G A Timony, Bryan Clemons
Publikováno v:
British Journal of Pharmacology. 173:1778-1792
Background and Purpose Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and endothelial barrier integrity. Stimulation of S1P1 receptors sequesters lymphocyte subsets in peripheral lym
Publikováno v:
Journal of Biological Chemistry. 266:8156-8161
Human tissue-type plasminogen activator (t-PA) is a glycoprotein used currently in thrombolytic therapy for patients with acute myocardial infarction. Due to its rapid rate of clearance from the circulation, continuous intravenous administration of a
Autor:
L B Angus, Glenn R. Larsen, G E Morris, K M Barone, P G Horgan, Ahern Tim J, G A Timony, J B Stoudemire, M J Brenner, P R Langer-Safer
Publikováno v:
Journal of Biological Chemistry. 266:3715-3723
A novel triple-kringle plasminogen activator protein, PK1 delta FE1X, has been produced which is a genetic chimera between the fibrin binding kringle 1 domain of plasminogen and the two kringles and serine protease domains of naturally occurring wild
Autor:
L B Angus, J B Stoudemire, Ahern Tim J, G A Timony, G E Morris, K S Henson, P G Horgan, K M Barone, P R Langer-Safer, Glenn R. Larsen
Publikováno v:
Journal of Biological Chemistry. 265:5540-5545
Recombinant variants of tissue plasminogen activator (t-PA) containing either substitutions or deletions of amino acids within the fibronectin finger-like domain (residues 6-50) were found to exhibit widely varying in vivo clearance profiles in rats
Autor:
K M, Brinkhous, J L, Sigman, M S, Read, P F, Stewart, K P, McCarthy, G A, Timony, S D, Leppanen, B J, Rup, J C, Keith, P D, Garzone, R G, Schaub
Publikováno v:
Blood. 88(7)
Recombinant human factor IX (rFIX) has been expressed in transduced cultured cell systems since 1985. Because there has been limited in vivo testing of rFIX in hemophilia B subjects, this study was undertaken using the severe hemophilia B canines of
Publikováno v:
The Journal of biological chemistry. 266(13)
Human tissue-type plasminogen activator (t-PA) is a glycoprotein used currently in thrombolytic therapy for patients with acute myocardial infarction. Due to its rapid rate of clearance from the circulation, continuous intravenous administration of a
Autor:
P R, Langer-Safer, T J, Ahern, L B, Angus, K M, Barone, M J, Brenner, P G, Horgan, G E, Morris, J B, Stoudemire, G A, Timony, G R, Larsen
Publikováno v:
The Journal of biological chemistry. 266(6)
A novel triple-kringle plasminogen activator protein, PK1 delta FE1X, has been produced which is a genetic chimera between the fibrin binding kringle 1 domain of plasminogen and the two kringles and serine protease domains of naturally occurring wild
Autor:
T J, Ahern, G E, Morris, K M, Barone, P G, Horgan, G A, Timony, L B, Angus, K S, Henson, J B, Stoudemire, P R, Langer-Safer, G R, Larsen
Publikováno v:
The Journal of biological chemistry. 265(10)
Recombinant variants of tissue plasminogen activator (t-PA) containing either substitutions or deletions of amino acids within the fibronectin finger-like domain (residues 6-50) were found to exhibit widely varying in vivo clearance profiles in rats
Publikováno v:
Radiation research. 117(2)
We have investigated the disposition of ethiofos (20 mg, 4 microCi [14C]ethiofos) in the isolated perfused rat liver preparation to determine the hepatic contribution to the poor oral bioavailability of the drug. Ethiofos clearance (10.6 +/- 3.3 ml h